Vogel C - Search Results

1

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).

Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). Abraham J, et al. Among authors: vogel c. Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4. Breast Cancer Res Treat. 2018. PMID: 29725889 Review.

2

Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature.

Davila E, Vogel CL, East D, Cairns V, Hilsenbeck S. Davila E, et al. Among authors: vogel cl. Cancer. 1988 Jun 1;61(11):2161-7. doi: 10.1002/1097-0142(19880601)61:11<2161::aid-cncr2820611105>3.0.co;2-2. Cancer. 1988. PMID: 2966667

3

Complete response in metastatic breast cancer.

Vogel C. Vogel C. Breast Cancer Res Treat. 1986;7(1):47-8. doi: 10.1007/BF01886737. Breast Cancer Res Treat. 1986. PMID: 3697514 No abstract available.

4

Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer.

Wang G, Vogel CL, Hilsenbeck SG, Voigt W, Thomsen S. Wang G, et al. Among authors: vogel cl. Breast Cancer Res Treat. 1984;4(4):283-8. doi: 10.1007/BF01806040. Breast Cancer Res Treat. 1984. PMID: 6518294

5

Phase II and III clinical trials of toremifene for metastatic breast cancer.

Vogel CL. Vogel CL. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):9-13. Oncology (Williston Park). 1998. PMID: 9556785 Free article. Review.

6

A review of vinorelbine in the treatment of breast cancer.

Domenech GH, Vogel CL. Domenech GH, et al. Among authors: vogel cl. Clin Breast Cancer. 2001 Jul;2(2):113-28. doi: 10.3816/CBC.2001.n.016. Clin Breast Cancer. 2001. PMID: 11899783 Review.

7

Weekly paclitaxel in women age 65 and above with metastatic breast cancer.

Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Perez EA, et al. Breast Cancer Res Treat. 2002 May;73(1):85-8. doi: 10.1023/a:1015230212550. Breast Cancer Res Treat. 2002. PMID: 12083634 Clinical Trial.

8

Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.

Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel CL. Franco S, et al. Among authors: vogel cl. Breast Cancer Res Treat. 2004 Nov;88(2):103-8. doi: 10.1007/s10549-004-0748-7. Breast Cancer Res Treat. 2004. PMID: 15564793 Clinical Trial.

9

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Mass RD, et al. Clin Breast Cancer. 2005 Aug;6(3):240-6. doi: 10.3816/CBC.2005.n.026. Clin Breast Cancer. 2005. PMID: 16137435

10

Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.

Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, Downey A, Vogel CL, Chia S, Muggia F. Andreopoulou E, et al. Clin Breast Cancer. 2007 Aug;7(9):690-6. doi: 10.3816/CBC.2007.n.028. Clin Breast Cancer. 2007. PMID: 17919349 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,127 results

Search Page

Filters